{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T16:44:45Z","timestamp":1785689085415,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04525-z","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T03:29:56Z","timestamp":1785641396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A radiotherapy-related fibrosis gene signature-based risk model for predicting prognosis and immunological features in lung adenocarcinoma"],"prefix":"10.1007","author":[{"given":"Yanyan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2217-8205","authenticated-orcid":false,"given":"Shubo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"issue":"9","key":"4525_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-104941","volume":"15","author":"X Ge","year":"2025","unstructured":"Ge X, Liu X, Xu WH, Sun Y, Lin H, Shen P, et al. Trends in the incidence of lung cancer in never smokers in Eastern China: a retrospective population-based cohort study using regional electronic health records. BMJ Open. 2025;15(9):e104941.","journal-title":"BMJ Open"},{"issue":"1","key":"4525_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00740-6","volume":"15","author":"J Lee","year":"2026","unstructured":"Lee J, Jeong JY, Hong MJ, Choi YH, Kim JY, Lee JH, et al. Defining the cellular and molecular identities of histologic subtypes in lung adenocarcinoma. Exp Hematol Oncol. 2026;15(1):12. https:\/\/doi.org\/10.1186\/s40164-025-00740-6.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"4525_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"4525_CR4","unstructured":"Kanchustambham V, Sharma S, Lung adenocarcinoma, StatPearls, StatPearls Publishing; 2026"},{"issue":"1","key":"4525_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44321-024-00175-2","volume":"17","author":"CY Chen","year":"2025","unstructured":"Chen CY, Huang KY, Chen CC, Chang YH, Li HJ, Wang TH, et al. The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications. EMBO Mol Med. 2025;17(1):31\u201340.","journal-title":"EMBO Mol Med"},{"key":"4525_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-002899","author":"SL Chang","year":"2025","unstructured":"Chang SL, Chuan PM, Lai CH, Yang HW, Chen YM, Hsu HS, et al. Greater lung cancer polygenic risk score in higher air pollution areas linked to greater rate of lung adenocarcinoma: a single-centre study in East Asia. BMJ Open Respir Res. 2025. https:\/\/doi.org\/10.1136\/bmjresp-2024-002899.","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"4525_CR7","first-page":"149","volume":"3","author":"CH Chao","year":"2025","unstructured":"Chao CH, Di YP. Mechanisms and current advances in treating KRAS-mutated lung cancer. Chin Med J (Engl). 2025;3(3):149\u201363.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"4525_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3658","volume":"26","author":"L Xu","year":"2024","unstructured":"Xu L, Ding R, Song S, Liu J, Li J, Ju X, et al. Single-cell RNA sequencing reveals the mechanism of PI3K\/AKT\/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation. J Gene Med. 2024;26(1):e3658.","journal-title":"J Gene Med"},{"key":"4525_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1533048","volume":"15","author":"L Chen","year":"2025","unstructured":"Chen L, Liu J, Lu J, Hu X, An E, Zhao Y. First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis. Front Oncol. 2025;15:1533048.","journal-title":"Front Oncol"},{"issue":"6","key":"4525_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70237","volume":"6","author":"P Wang","year":"2025","unstructured":"Wang P, Zhang C, Wu P, Zhao Z, Sun N, Xue Q, et al. Cell death and senescence-based molecular classification and an individualized prediction model for lung adenocarcinoma. MedComm. 2025;6(6):e70237.","journal-title":"MedComm"},{"key":"4525_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105089","volume":"103","author":"M Fijardo","year":"2024","unstructured":"Fijardo M, Kwan JYY, Bissey PA, Citrin DE, Yip KW, Liu FF. The clinical manifestations and molecular pathogenesis of radiation fibrosis. EBioMedicine. 2024;103:e105089.","journal-title":"EBioMedicine"},{"issue":"1","key":"4525_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13014-020-01654-9","volume":"15","author":"L K\u00e4smann","year":"2020","unstructured":"K\u00e4smann L, Dietrich A, Staab-Weijnitz CA, Manapov F, Behr J, Rimner A, et al. Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol (London, England). 2020;15(1):214. https:\/\/doi.org\/10.1186\/s13014-020-01654-9.","journal-title":"Radiat Oncol (London, England)"},{"issue":"11","key":"4525_CR13","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24(11):1206\u201318.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4525_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-025-02617-8","volume":"20","author":"S Wang","year":"2025","unstructured":"Wang S, Xu D, Xiao L, Liu B, Yuan X. Radiation-induced lung injury: from mechanism to prognosis and drug therapy. Radiat Oncol. 2025;20(1):39. https:\/\/doi.org\/10.1186\/s13014-025-02617-8.","journal-title":"Radiat Oncol"},{"issue":"1","key":"4525_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52828-4","volume":"14","author":"S Dammak","year":"2024","unstructured":"Dammak S, Gulstene S, Palma DA, Mattonen SA, Senan S, Ward AD. Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics. Sci Rep. 2024;14(1):e3758.","journal-title":"Sci Rep"},{"key":"4525_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1180723","volume":"13","author":"L Dong","year":"2023","unstructured":"Dong L, Fu L, Zhu T, Wu Y, Li Z, Ding J, et al. A five-collagen-based risk model in lung adenocarcinoma: prognostic significance and immune landscape. Front Oncol. 2023;13:e1180723.","journal-title":"Front Oncol"},{"issue":"46","key":"4525_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045756","volume":"104","author":"Y Ma","year":"2025","unstructured":"Ma Y, Li X, Wang X, Song B, Geng R, Hao Y, et al. Identification and validation of a diagnostic and prognostic model based on immune escape and cancer-associated fibroblast-related genes in lung adenocarcinoma. Medicine (Baltimore). 2025;104(46):e45756.","journal-title":"Medicine (Baltimore)"},{"issue":"177","key":"4525_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0192-2024","volume":"34","author":"N El-Merhie","year":"2025","unstructured":"El-Merhie N, Staab-Weijnitz CA, Burgess JK, Kwapiszewska G. Beyond classical collagen: basement membrane collagen IV in age-associated lung diseases. Eur Respir Rev. 2025;34(177):e240192.","journal-title":"Eur Respir Rev"},{"issue":"13","key":"4525_CR19","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.7150\/jca.115525","volume":"16","author":"P Tang","year":"2025","unstructured":"Tang P, Zhang R, Zhang Y, Ao Y, Wang Y, Wang G, et al. CD40LG downregulation in lung adenocarcinoma: a prognostic biomarker linked to immune cell infiltration and survival outcomes. J Cancer. 2025;16(13):3884\u201396.","journal-title":"J Cancer"},{"key":"4525_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107709","volume":"219","author":"T Tang","year":"2021","unstructured":"Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol Ther. 2021;219:e107709.","journal-title":"Pharmacol Ther"},{"key":"4525_CR21","doi-asserted-by":"publisher","first-page":"7840652","DOI":"10.1155\/2020\/7840652","volume":"2020","author":"W Cheng","year":"2020","unstructured":"Cheng W, Wang F, Feng A, Li X, Yu W. CXXC5 attenuates pulmonary fibrosis in a bleomycin-induced mouse model and MLFs by suppression of the CD40\/CD40L pathway. Biomed Res Int. 2020;2020:7840652.","journal-title":"Biomed Res Int"},{"key":"4525_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215611","volume":"536","author":"H Chen","year":"2022","unstructured":"Chen H, Zhao L, Meng Y, Qian X, Fan Y, Zhang Q, et al. Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression. Cancer Lett. 2022;536:e215611.","journal-title":"Cancer Lett"},{"issue":"2","key":"4525_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1667\/RR15381.1","volume":"193","author":"P Xia","year":"2020","unstructured":"Xia P, Cao K, Hu X, Liu L, Yu D, Dong S, et al. K(ATP) channel blocker glibenclamide prevents radiation-induced lung injury and inhibits radiation-induced apoptosis of vascular endothelial cells by increased Ca(2+) influx and subsequent PKC activation. Radiat Res. 2020;193(2):171\u201385.","journal-title":"Radiat Res"},{"issue":"1","key":"4525_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01838-9","volume":"9","author":"F He","year":"2024","unstructured":"He F, Wu Z, Liu C, Zhu Y, Zhou Y, Tian E, et al. Targeting BCL9\/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal Transduct Target Ther. 2024;9(1):e139.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4525_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.drudis.2021.01.002","volume":"26","author":"S Kumar","year":"2021","unstructured":"Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8(+) T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today. 2021;26(4):951\u201367.","journal-title":"Drug Discov Today"},{"issue":"23","key":"4525_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312848","volume":"25","author":"O Franzese","year":"2024","unstructured":"Franzese O. Tumor microenvironment drives the cross-talk between co-stimulatory and inhibitory molecules in tumor-infiltrating lymphocytes: implications for optimizing immunotherapy outcomes. Int J Mol Sci. 2024;25(23):12848. https:\/\/doi.org\/10.3390\/ijms252312848.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4525_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"YT Liu","year":"2025","unstructured":"Liu YT, Wang YL, Wang S, Li JJ, He W, Fan XJ, et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol Cancer. 2025;24(1):e254.","journal-title":"Mol Cancer"},{"issue":"1","key":"4525_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin K, Hou H, Liang Y, Zhang X. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer. 2020;20(1):e328.","journal-title":"BMC Cancer"},{"issue":"9","key":"4525_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101163","volume":"14","author":"R Yu","year":"2021","unstructured":"Yu R, Bai H, Li T, Gao B, Han J, Chang G, et al. TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. Transl Oncol. 2021;14(9):e101163.","journal-title":"Transl Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04525-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T16:02:04Z","timestamp":1785686524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04525-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":29,"alternative-id":["4525"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04525-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not include any human or animal subjects.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}